Song YuYing, Feng NaNa, Yu QingYa, Li YuanYuan, Meng MingKun, Yang Xing, Gan ZhiQiang, Xu Tong, Tang Ce, Zhang Yi
State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 611137, People's Republic of China.
School of Ethnic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 611137, People's Republic of China.
Int J Nanomedicine. 2025 Aug 30;20:10613-10644. doi: 10.2147/IJN.S540094. eCollection 2025.
Exosomes are nano-sized extracellular vesicles secreted by diverse cell types that mediate intercellular communication through the transfer of proteins, lipids, and nucleic acids. Their ability to cross biological barriers and carry bioactive cargo has led to increasing interest in their use as targeted delivery systems for drugs, genes, and immunomodulatory molecules. Recently, plant-derived exosome-like nanoparticles, PLNs obtained from edible plants and medicinal herbs have emerged as a novel, biocompatible alternative to mammalian exosomes. PLNs exhibit low immunogenicity, enhanced safety, and scalable production, making them ideal candidates for clinical translation. This review synthesizes a wide body of experimental data on the biogenesis, molecular composition, and biological activity of PLNs, and provides a comparative assessment of their therapeutic applications across oncology, immunotherapy, regenerative medicine, and gene therapy. Technological advances in PLN engineering, isolation, and manufacturing are discussed, along with key translational barriers such as stability, regulatory standards, and delivery specificity. This review also discusses the scientific implications of PLNs in advancing precision medicine and propose future directions for their integration into next-generation nanotherapeutics.
外泌体是由多种细胞类型分泌的纳米级细胞外囊泡,通过蛋白质、脂质和核酸的传递介导细胞间通讯。它们穿越生物屏障并携带生物活性物质的能力,使得人们对将其用作药物、基因和免疫调节分子的靶向递送系统的兴趣日益增加。最近,从可食用植物和药草中获得的植物源外泌体样纳米颗粒(PLNs)已成为一种新型的、具有生物相容性的替代哺乳动物外泌体的物质。PLNs具有低免疫原性、更高的安全性和可扩展的生产能力,使其成为临床转化的理想候选者。本综述综合了大量关于PLNs的生物发生、分子组成和生物活性的实验数据,并对其在肿瘤学、免疫治疗、再生医学和基因治疗中的治疗应用进行了比较评估。讨论了PLN工程、分离和制造方面的技术进展,以及诸如稳定性、监管标准和递送特异性等关键转化障碍。本综述还讨论了PLNs在推进精准医学方面的科学意义,并提出了将其整合到下一代纳米治疗中的未来方向。